Poisoning of Mitochondrial Topoisomerase I by Lamellarin D
暂无分享,去创建一个
Y. Pommier | K. Neuman | Hongliang Zhang | S. Khiati | K. Agama | Yeonee Seol | I. D. Rosa | Surbhi Agrawal | Katherine Fesen
[1] Justin J. Wilson,et al. Targeting mitochondrial DNA with a platinum-based anticancer agent. , 2013, Chemistry & biology.
[2] Morten O. Christensen,et al. Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I , 2013, Nucleic acids research.
[3] J. Neuzil,et al. Classification of mitocans, anti-cancer drugs acting on mitochondria. , 2013, Mitochondrion.
[4] S. Kelley,et al. Targeted delivery of doxorubicin to mitochondria. , 2013, ACS chemical biology.
[5] A. Szewczyk,et al. Mitochondria as a pharmacological target: Magnum overview , 2013, IUBMB life.
[6] Y. Pommier. Drugging topoisomerases: lessons and challenges. , 2013, ACS chemical biology.
[7] Y. Pommier,et al. A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity , 2012, Proceedings of the National Academy of Sciences.
[8] S. Dhar,et al. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics , 2012, Proceedings of the National Academy of Sciences.
[9] G. Brockhoff,et al. Targeting drugs to mitochondria. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[10] Y. Pommier,et al. Mitochondrial Topoisomerase I is Critical for Mitochondrial Integrity and Cellular Energy Metabolism , 2012, PloS one.
[11] Raquel Herrador,et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal , 2012, Nature Structural &Molecular Biology.
[12] Yves Pommier,et al. Interfacial inhibitors: targeting macromolecular complexes , 2012, Nature Reviews Drug Discovery.
[13] J. Edwards,et al. Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. , 2011, American journal of physiology. Cell physiology.
[14] Yuxin Cui,et al. Total synthesis of lamellarins D, H, and R and ningalin B. , 2011, Organic letters.
[15] Y. Pommier,et al. Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria , 2010, Proceedings of the National Academy of Sciences.
[16] N. Osheroff,et al. The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I , 2010, Nucleic acids research.
[17] Joel N. Meyer,et al. The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number. , 2010, Methods.
[18] Yves Pommier,et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. , 2010, Chemistry & biology.
[19] C. Chi,et al. Mitochondrial DNA Content as a Potential Marker to Predict Response to Anthracycline in Breast Cancer Patients , 2010, The breast journal.
[20] Christian Bailly,et al. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D , 2010, Apoptosis.
[21] Christian Bailly,et al. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D , 2009, Molecular Cancer Therapeutics.
[22] S. Kelley,et al. Targeting Mitochondria with Organelle‐Specific Compounds: Strategies and Applications , 2009, Chembiochem : a European journal of chemical biology.
[23] Yidong Bai,et al. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis , 2009, Cell Research.
[24] Y. Pommier,et al. DNA cleavage assay for the identification of topoisomerase I inhibitors , 2008, Nature Protocols.
[25] Y. Pommier,et al. Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA. , 2008, Biochemistry.
[26] F. Albericio,et al. Recent advances in lamellarin alkaloids: isolation, synthesis and activity. , 2008, Anti-cancer agents in medicinal chemistry.
[27] T. Mizumachi,et al. Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line , 2007, International journal of cancer.
[28] Y. Pommier,et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. , 2007, Cancer research.
[29] Daniel A. Koster,et al. Antitumour drugs impede DNA uncoiling by topoisomerase I , 2007, Nature.
[30] Jérôme Kluza,et al. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. , 2006, Cancer research.
[31] R. Millikan,et al. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. , 2005, Cancer research.
[32] Y. Pommier,et al. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. , 2005, Journal of medicinal chemistry.
[33] Guido Davidzon,et al. Mitochondrial DNA and disease , 2005, Annals of medicine.
[34] John A. Hall,et al. mtDNA mutations increase tumorigenicity in prostate cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[35] C. Bailly. Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. , 2004, Current medicinal chemistry. Anti-cancer agents.
[36] Christian Bailly,et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. , 2003, Cancer research.
[37] D. Friedman,et al. A truncated form of DNA topoisomerase IIbeta associates with the mtDNA genome in mammalian mitochondria. , 2003, European journal of biochemistry.
[38] James C. Wang,et al. Dual localization of human DNA topoisomerase IIIα to mitochondria and nucleus , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[39] Y. Pommier,et al. Human mitochondrial topoisomerase I , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] V. Weissig,et al. Mitochondrial DNA metabolism targeting drugs. , 2001, Advanced drug delivery reviews.
[41] Keshav K. Singh,et al. Mitochondrial DNA determines the cellular response to cancer therapeutic agents , 1999, Oncogene.
[42] Y. Pommier,et al. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] Y. Pommier,et al. Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.
[44] W G Hol,et al. A model for the mechanism of human topoisomerase I. , 1998, Science.
[45] E. Kraut,et al. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. , 1995, Cancer research.
[46] Y. Pommier,et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.
[47] T. Burke,et al. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. , 1994, Journal of medicinal chemistry.
[48] K. Kohn,et al. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. , 1989, Cancer research.
[49] J. Wang,et al. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Hertzberg,et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.
[51] P. Slonimski,et al. Mitochondrial genetics , 2004, Molecular and General Genetics MGG.
[52] James C. Wang,et al. Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[53] D. A. Clayton,et al. Replication and transcription of vertebrate mitochondrial DNA. , 1991, Annual review of cell biology.